<p>NUT midline carcinoma of the head and neck: current perspectives</p>Martina Napolitano(University of Modena and Reggio Emilia), Angela Toss(University of Modena and Reggio Emilia)OncoTargets and TherapyApril 1, 201910.2147/ott.s173056Cited by 58SaveCiteExport RISWatch citationsRelated PapersComparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2.|Journal of Clinical Oncology|2024|7Abstract P2-09-26: Real world progression free survival in elderly vs. younger HR+/HER2- advanced breast cancer patients treated with first-line endocrine therapy plus CDK4/6i: a sub-analysis of the multicenter, PALMARES-2 study|Clinical Cancer Research|2025|0